WUSM CANCER AND LEUKEMIA GROUP B

描述（根据申请人摘要改编）：华盛顿大学 自1986年以来一直是CALGB的主要成员机构。 由于钥匙丢失 人员和有限的集团范围内的CALGB资金，我们没有资助期间， 上一个赠款周期。 因此，这一建议是一个新的 申请重建华盛顿大学 资助了CALGB的科学活动。 1994年，华盛顿大学 招募了国家肺癌治疗专家丹尼尔·伊德博士 造血干细胞生物学专家John DiPersio博士， 骨髓移植和干细胞生物学系主任。 自加入教师队伍以来，伊德博士一直担任华盛顿大学的 CALGB首席研究员。 lhde博士和DiPersio博士都有很强的 致力于临床研究，并招募和培养了许多新的 临床研究者。 该大学被授予国家癌症 1995年7月获得癌症中心规划补助金。 Ihde博士和Dr. Stanley Korsmeyer领导癌症中心的规划工作， 促进了临床和基础科学之间的积极合作 在过去的18个月里。 其中许多合作 进行了新的机构试点研究，包括对新的 多药耐药性调节剂和程序性细胞死亡的调节剂。 有希望的试点研究将提交给CALGB委员会， 在下一个赠款周期纳入组协议，因为博士。 lhde的招聘，华盛顿大学的承诺，CALGB一直是 以几种方式证明。 应计项目从1994年的52个增加到118个 1996年 我们的数据管理得到了极大的改善， 最近的IPEC报告将我们置于CALGB机构的前三分之一， 完整性和一致性。 科学研究人员人数 委员会从1993年的5个增加到目前的18个。 十一 正在进行的、最近结束的或拟议中的研究由华盛顿主持 大学调查员。 三名成员参加了现场审核 访问、成员委员会和利益冲突委员会。 我们庞大的患者基础将帮助我们在 未来几年。 巴恩斯犹太医院，最大的医院在圣。 路易斯每年诊断出4,000多名癌症患者， 密苏里州东南部和伊利诺斯州南部的主要转诊中心。 我们 预计在未来五年内， 建设我们新的批准和资助的最先进的临床癌症 中心大楼预计2000年完工。

DESCRIPTION (adapted from the applicant's abstract): Washington University has been a CALGB main member institution since 1986. Due to loss of key personnel and limited groupwide CALGB funding, we were not funded during the previous grant cycle. Therefore, this proposal serves as a new institutional application to re-establish Washington University in the funded scientific activities of the CALGB. In 1994, Washington University recruited Dr. Daniel Ihde, a national expert in the treatment of lung cancer and Dr. John DiPersio, an expert in hematopoietic stem cell biology, as Chief of the Division of Bone Marrow Transplantation and Stem Cell Biology. Since joining the faculty, Dr. Ihde has served as Washington University's CALGB Principal Investigator. Both Drs. lhde and DiPersio have a strong commitment to clinical research and have recruited and fostered many new clinical Investigators. The University was awarded a National Cancer Institute Cancer Center Planning Grant in July, 1995. Dr. Ihde and Dr. Stanley Korsmeyer lead the Cancer Center planning efforts and have stimulated vigorous collaboration between clinical and basic science investigators over the last 18 months. Many of these collaborations have resulted in new institutional pilot studies, including studies of new multidrug resistance modulators and regulators of programmed cell death. Promising pilot studies will be presented to CALGB committees for possible incorporation into group protocols during the next grant cycle, Since Dr. lhde's recruitment, Washington University's commitment to CALGB has been demonstrated in several ways. Accrual has increased from 52 in 1994 to 118 in 1996. Our data management has improved substantially with our most recent IPEC report placing us in the top one third of CALGB institutions in completeness and consistency. The number of investigators on scientific committees has increased from five in 1993 to eighteen at present. Eleven current, recently closed, or proposed studies are chaired by Washington University investigators. Three members have participated in audit site visits, the membership committee, and the conflict of interest committee. Our large patient base will help us maintain excellent CALGB accrual during the coming years. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 4,000 patients a year with cancer and is the major referral center for southeast Missouri and southern Illinois. We expect referrals to increase significantly over the next five years with the construction of our new approved and funded state-of-the-art clinical cancer center building which is projected to be completed in 2000.